



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/822,354
				Filing Date	April 12, 2004
				First Named Inventor	Bob M. Moore II
				Group Art Unit	1614
				Examiner Name	SPIVACK
Sheet	1	of	3	Attorney's Docket No.	747.0037

U.S. Patent Documents						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, columns, lines where passages or relevant figures appear
		Number Code	Kind			
PS	AA	5,939,429		Kunos et al	08-17-99	
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

P. Spivack 7/10/05

Sheet	2	of	3		Inventor:	Bob M. Moore II
-------	---	----	---	--	-----------	-----------------

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	FOREIGN PATENT DOCUMENTS			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, columns, lines where passages or relevant figures appear	T ²
		Office code	Number	Kind				
PS	BA		WO 03/042174		Friary, et al	05/22/03	16; lines 13-19 Claim 44	
	BB							
	BC							
	BD							
	BE							
	BF							
	BG							
	BH							
	BI							
	BJ							

Examiner Signature	P. Spivack	Date Considered	7/10/05
-----------------------	------------	--------------------	---------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.

Sheet	3	of	3	Inventor:	Bob M. Moore II
-------	---	----	---	-----------	-----------------

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published			T ²
PS	C A	DILGER, K., et al., "Effects of Celecoxib and Diclofenac on blood pressure, renal function, and vasoactive prstanoids in young and elderly subjects", J. Clin. Pharmacology, 42:985-994 (2002)			
	C B	HILLARD, CJ, "Endocannabinoids and vascular function", J. Pharmacology and Experimental Therapeutics, 294(1):27-32 ((2000)			
	C C	BROWN, DJ, et al., "The influence of Δ9-tetrahydrocannabinol on cardiovascular and subcutaneous microcirculatory systems in the bat", J. Pharmacology and Experimental Therapeutics, 188(3):624-629 (1974)			
	C D	KUNOS, G., et al., "Endocannabinoids as cardiovascular modulators", Chemistry and Physics of Lipids, 108:159-168 (2000)			
	C E	WAGNER, JA, et al., "Cardiovascular actions of cannabinoids and their generation during shock", J. Mol. Med., 76:824-836 (1998)			
	C F	ADAMS, MD, et al., "Vasoconstrictor Actions of Δ8- and Δ9- tetrahydrocannabinol in the rat", J. Pharmacology and Experimental Therapeutics, 196(3):649-656 (1976)			
	C G	WAGNER, JA, et al., "Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock", Nature,390:518-521 (1997)			
	C H	JOHNSON, DL, et al., "Effect of Cyclooxygenase-2 inhibitors on blood pressure", The Annals of Pharmacology, 37:442-446 (2003)			
	C I	KUNOS, G., et al., "Cardiovascular effects of endocannabinoids - the plot thickens", Prostaglandin & Other Lipid Mediators, 61:71-84(2000)			
	C J	LAKE, KD, et al., "Cannabinoid-Induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors", J. Pharmacology and Experimental Therapeutics, 281(3):1030-1037 (1997)			
✓	C K	SIQUEIRA, SW, et al., "The triple effect induced by Δ9-tetrahydrocannabinol on the rat blood pressure", European Journal of Pharmacology, 58:351-357 (1979)			

Examiner Signature	P. Spivack	Date Considered	7/10/05
--------------------	------------	-----------------	---------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/822,354
				Filing Date	April 12, 2004
				First Named Inventor	Bob M. Moore II
				Group Art Unit	1614
				Examiner Name	SPIVACK
Sheet	1	of	3	Attorney's Docket No.	747.0037

U.S. Patent Documents						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, columns, lines where passages or relevant figures appear
		Number Code	Kind			
NS	AA	5,939,429		Kunos et al	08-17-99	
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

BEST AVAILABLE COPY

P. Spivack 7/10/05

Sheet	2	of	3		Inventor:	Bob M. Moore II
-------	---	----	---	--	-----------	-----------------

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	FOREIGN PATENT DOCUMENTS			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, columns, lines where passages or relevant figures appear	T ²
		Office code	Number	Kind				
PS	B A		WO 03/042174		Friary, et al	05/22/03	16; lines 13-19 Claim 44	
	B B							
	B C							
	B D							
	B E							
	B F							
	B G							
	B H							
	B I							
	B J							

Examiner Signature	P. Spivack	Date Considered	7/10/05
-----------------------	------------	--------------------	---------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.

Sheet	3	of	3	Inventor:	Bob M. Moore II
-------	---	----	---	-----------	-----------------

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite, No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published			T ²
PS	C A	DILGER, K., et al., "Effects of Celecoxib and Diclofenac on blood pressure, renal function, and vasoactive prstanoids in young and elderly subjects", J. Clin. Pharmacology, 42:985-994 (2002)			
	C B	HILLARD, CJ, "Endocannabinoids and vascular function", J. Pharmacology and Experimental Therapeutics, 294(1):27-32 ((2000)			
	C C	BROWN, DJ, et al., "The influence of Δ9-tetrahydrocannabinol on cardiovascular and subcutaneous microcirculatory systems in the bat", J. Pharmacology and Experimental Therapeutics, 188(3):624-629 (1974)			
	C D	KUNOS, G., et al., "Endocannabinoids as cardiovascular modulators", Chemistry and Physics of Lipids, 108:159-168 (2000)			
	C E	WAGNER, JA, et al., "Cardiovascular actions of cannabinoids and their generation during shock", J. Mol. Med., 76:824-836 (1998)			
	C F	ADAMS, MD, et al., "Vasoconstrictor Actions of Δ8- and Δ9- tetrahydrocannabinol in the rat", J. Pharmacology and Experimental Therapeutics, 196(3):649-656 (1976)			
	C G	WAGNER, JA, et al., "Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock", Nature,390:518-521 (1997)			
	C H	JOHNSON, DL, et al., "Effect of Cyclooxygenase-2 inhibitors on blood pressure", The Annals of Pharmacology, 37:442-446 (2003)			
	C I	KUNOS, G., et al., "Cardiovascular effects of endocannabinoids - the plot thickens", Prostaglandin & Other Lipid Mediators, 61:71-84(2000)			
	C J	LAKE, KD, et al., "Cannabinoid-Induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors", J. Pharmacology and Experimental Therapeutics, 281(3):1030-1037 (1997)			
✓	C K	SIQUEIRA, SW, et al., "The triple effect induced by Δ9-tetrahydrocannabinol on the rat blood pressure", European Journal of Pharmacology, 58:351-357 (1979)			

Examiner Signature	P. Spivack	Date Considered	7/10/05
--------------------	------------	-----------------	---------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.